Page 13 - ARNM-2-1

Advances in Radiotherapy
& Nuclear Medicine Pediatric myelosuppression in radiotherapy

Table 7. Description of baseline data before and after propensity matching according to age
Variants Before matching After matching P‑value
Age≤10 years (n=20) Age>10 years (n=29) Age≤10 years (n=14) Age>10 years (n=14)
Gender
Male 11 22 11 10 1
Female 9 7 3 4
Prescribed dose (Gy) 23.25 (21.225, 33) 50 (30, 60) 24 (21, 47.5) 26.65 (22, 50) 0.30
Treatment fraction 12 (11, 17) 20 (15, 30) 12 (11, 24) 13 (11, 24) 0.59
Duration of treatment (days) 16 (14, 28) 28 (14, 37) 17 (15, 29) 16 (15, 34) 0.85
Note: The values are presented as median (quartile ranges) for prescribed dose, treatment fraction, and duration of treatment.

Table 8. Relationship between age after propensity matching Conflict of interest
and bone marrow suppression after radiotherapy
The authors declare that they have no competing interests.
Myelosuppression Age≤10 years Age>10 years
after radiotherapy Author contributions
Yes 7 8 Conceptualization: Yibao Zhang
No 7 6 Formal analysis: Yijie Sun, Chenguang Li
Investigation: Hongjia Liu, Chenguang Li, Huamu Xie
In summary, based on data from 49 radiotherapy patients Methodology: Yijie Sun, Hongjia Liu
under 15 years old, our study revealed that the incidence of Writing – original draft: Yijie Sun
myelosuppression of grade II or higher was approximately Writing – review & editing: Yibao Zhang
twice as high as that in adults, suggesting that the dynamic
changes in the distribution of red bone marrow with age Ethics approval and consent to participate
should be taken into account in protocol optimization for Ethical approval was obtained for this retrospective study
pediatric patients. In addition, beyond traditional focus areas (IRB#2019YJZ76) from the Peking University Cancer
such as the pelvic region and red bone marrow in the head- Hospital and Institute, China.
and-neck region should be considered in pediatric patients.
In addition, other factors affecting radiotherapy should Consent for publication
also be taken into consideration. 19,20 Additional age-group- Waiver of informed consent applies to this retrospective
based segmentation strategies for pediatric patients require study.
support from prospective large-sample studies.
Availability of data
5. Conclusion
Data used in this work are available from the corresponding
This study revealed that there was higher incidence of author on reasonable request.
myelosuppression of grade II or higher in pediatric patients
than in adults. However, no significant association was References
observed between age or gender and radiation-induced
myelosuppression. These results underscore the importance 1. Force LM, Abdollahpour I, Advani SM, et al. The global
of carefully considering radiation-induced myelosuppression burden of childhood and adolescent cancer in 2017: An
analysis of the Global Burden of Disease Study 2017. Lancet
during the protocol optimization of radiotherapy.
Oncol. 2019;20(9):1211-1225.
Acknowledgments doi: 10.1016/s1470-2045(19)30339-0

None. 2. Steinmeier T, Schleithoff SS, Timmermann B. Evolving
radiotherapy techniques in paediatric oncology. Clin Oncol
Funding (R Coll Radiol). 2019;31(3):142-150.

This study was supported by the National Nature Science doi: 10.1016/j.clon.2018.12.005
Foundation of China (award number: 12275012) and 3. Hindorf C, Glatting G, Chiesa C, Lindén O, Flux G.
the Natural Science Foundation of Beijing Municipality EANM Dosimetry committee guidelines for bone marrow
(award number: Z210008). and whole-body dosimetry. Eur J Nucl Med Mol Imaging.

Volume 2 Issue 1 (2024) 5 https://doi.org/10.36922/arnm.2519